𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells

✍ Scribed by Dong Mi; Ming Zhang; Ji-dong Yan; Jie Zhang; Xu Wang; Qing Wang; Shuang Yang; Tian-hui Zhu


Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
462 KB
Volume
137
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Antisense glutaminase inhibition modifie
✍ Ana C. Donadio; Carolina Lobo; Marta Tosina; Vanessa de la Rosa; Mercedes Martín 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 263 KB

## Abstract Glutamine behaves as a key nutrient for tumors and rapidly dividing cells. Glutaminase is the main glutamine‐utilizing enzyme in these cells, and its activity correlates with glutamine consumption and growth rate. We have carried out the antisense L‐type glutaminase inhibition in human

Raloxifene induces cell death and inhibi
✍ V. Rossi; G. Bellastella; C. De Rosa; C. Abbondanza; D. Visconti; L. Maione; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

## Abstract Raloxifene (RAL), a selective estrogen receptor (ER) modulator (SERM) seems to induce apoptosis in both androgen‐dependent and ‐independent prostate cell (PC) lines via activation of ERβ and an antagonistic effect on ERα. In this study, we evaluated the effects of RAL on epithelial PC g

Suppression of integrin αυβ6 by RNA inte
✍ Jiayong Wang; Zhaoyang Zhang; Kesen Xu; Xiaohui Sun; Guangyun Yang; Weibo Niu; E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 311 KB

## Abstract Integrin αυβ6 plays a very important role in the progression of colon cancer cells and is now defined as a novel, independent prognostic indicator for aggressive colon cancer in humans. Herein, we use the RNA interfering technology to downregulate the expression of αυβ6 in colon cancer

Bidirectional interactions between the e
✍ Thomas W. Grunt; Miguel Saceda; Mary Beth Martin; Ruth Lupu; Evelyn Dittrich; Ge 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 993 KB

The responsiveness of estrogen receptor (ER)-positive breast cancer to endocrine therapy is frequently reduced in cells over-expressing c-erbB-2. Stimulation of ER suppresses c-erbB-2, indicating that estrogen controls the activity of c-erbB-2. Heregulin (HRG) has been described to bind to c-erbB-3/